Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
2025
|
| Subjects: | |
| Online Access: | https://pubmed.ncbi.nlm.nih.gov/39955851/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy. Sheykhhasan, Mohsen Ahmadieh-Yazdi, Amirhossein Heidari, Reza Chamanara, Mohsen Akbari, Mohammad Poondla, Naresh Yang, Piao Malih, Sara Manoochehri, Hamed Tanzadehpanah, Hamid Mahaki, Hanie Fayazi Hosseini, Nashmin Dirbaziyan, Ashkan Al-Musawi, Sharafaldin Kalhor, Naser Humans Dendritic Cells Cancer Vaccines Neoplasms Immunotherapy Animals Tumor Microenvironment In the modern time, cancer immunotherapies have increasingly become vital treatment options, joining long-established methods like surgery, chemotherapy, and radiotherapy treatment. Central to this emerging approach are dendritic cells (DCs), which boast a remarkable ability for antigen presentation. This ability is being leveraged to modulate T and B cell immunity, offering a groundbreaking strategy for tackling cancer. However, the percentage of patients experiencing meaningful benefits from this treatment remains relatively low, underscoring the ongoing necessity for further research and development in this field. This review offers a comprehensive analysis of the present-day progress in dendritic cell (DC)-based vaccines and recent efforts to enhance their efficacy. We explore the intricacies of DC function, from antigen capture to T cell stimulation, and discuss the outcomes of both preclinical and clinical trials across various cancer types. While the results are promising, the real-world application of DC-based vaccines is still nascent, posing multiple challenges that need to be overcome. These obstacles include optimizing the methods for DC generation and antigen loading, overcoming the immunosuppressive nature of the tumor microenvironment, and enhancing specificities of the immunologic response through personalized vaccines. The review concludes by emphasizing prospective opportunities for future research and emphasizing the critical need for extensive clinical trials. These trials are essential to validate the effectivity of DC-based vaccines and solidify their role in the broader spectrum of cancer immunotherapy options.